STOCK TITAN

Citius Pharmaceuticals Announces Closing of $15 Million Registered Direct Offering

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags

Citius Pharmaceuticals Inc. (Nasdaq: CTXR) closed a registered direct offering, raising $15 million through the sale of 21,428,574 shares and warrants. The offering was facilitated by H.C. Wainwright & Co. The company plans to utilize the funds for general corporate purposes, including product development and working capital.

Citius Pharmaceuticals Inc. (Nasdaq: CTXR) ha chiuso un'offerta diretta registrata, raccogliendo 15 milioni di dollari attraverso la vendita di 21.428.574 azioni e warrant. L'operazione è stata facilitata da H.C. Wainwright & Co. La compagnia prevede di utilizzare i fondi per scopi aziendali generali, inclusi lo sviluppo di prodotti e il capitale circolante.
Citius Pharmaceuticals Inc. (Nasdaq: CTXR) concluyó una oferta directa registrada, recaudando 15 millones de dólares mediante la venta de 21.428.574 acciones y warrants. La oferta fue facilitada por H.C. Wainwright & Co. La compañía planea utilizar los fondos para propósitos corporativos generales, incluyendo el desarrollo de productos y capital de trabajo.
시티어스 파마슈티컬스 인크(Nasdaq: CTXR)는 등록 직접 제공을 마감하여 2천1백4십2만8천5백74주의 주식과 워런트 판매를 통해 1천5백만 달러를 조달했습니다. 이 제공은 H.C. 웨인라이트 & Co에 의해 촉진되었습니다. 회사는 이 자금을 제품 개발 및 운영 자본을 포함한 일반 기업 목적으로 사용할 계획입니다.
Citius Pharmaceuticals Inc. (Nasdaq: CTXR) a clôturé une offre directe enregistrée, levant 15 millions de dollars grâce à la vente de 21.428.574 actions et warrants. L'offre a été facilitée par H.C. Wainwright & Co. La société prévoit d'utiliser les fonds pour des fins corporatives générales, y compris le développement de produits et le fonds de roulement.
Citius Pharmaceuticals Inc. (Nasdaq: CTXR) hat ein eingetragenes Direktangebot abgeschlossen, wobei 15 Millionen US-Dollar durch den Verkauf von 21.428.574 Aktien und Warrants erzielt wurden. Die Durchführung wurde von H.C. Wainwright & Co. erleichtert. Das Unternehmen plant, die Mittel für allgemeine Unternehmenszwecke zu verwenden, einschließlich Produktentwicklung und Betriebskapital.
Positive
  • None.
Negative
  • None.

The closing of Citius Pharmaceuticals' $15 million registered direct offering is a liquidity event that has several implications for the company's financial health and future operations. The issuance of over 21 million shares, together with the accompanying warrants, dilutes existing shareholders. However, the capital injection strengthens the company's balance sheet, providing necessary funds for ongoing clinical development programmes, working capital and potential capital expenditures. The exercise price of $0.75 per share for the warrants suggests a modest premium to the offering price, which could be indicative of management’s confidence in the future growth of the stock price. Furthermore, the involvement of a reputable placement agent like H.C. Wainwright & Co. often reassures investors of the offering's legitimacy and the potential for professional due diligence.

For retail investors, the closing of this offering signals Citius Pharmaceuticals' move to secure funding without resorting to more debt or traditional equity financing, which could be more dilutive or costly. The use of a 'shelf' registration indicates a pre-planned financing strategy, allowing for the company to sell securities to the public with reduced administrative turnaround time. This agility can be important for biopharmaceutical companies like Citius that must rapidly respond to funding needs during different stages of drug development. Investors should monitor how effectively Citius deploys the raised capital into their critical care product pipeline, as the efficient use of funds can lead to value creation over time.

CRANFORD, N.J., April 30, 2024 /PRNewswire/ -- Citius Pharmaceuticals Inc. (Nasdaq: CTXR) ("Citius" or the "Company"), a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, today announced that it has closed its previously announced registered direct offering for the purchase of an aggregate of 21,428,574 shares of its common stock and accompanying warrants to purchase up to an aggregate of 21,428,574 shares of its common stock, at a purchase price of $0.70 per share and accompanying warrant. The warrants have an exercise price of $0.75 per share, will be exercisable six months from the date of issuance, and will expire five years from the initial exercise date.

H.C. Wainwright & Co. acted as the exclusive placement agent for the offering.

The aggregate gross proceeds to the Company from the offering were approximately $15 million, before deducting the placement agent fees and other offering expenses payable by the Company. Citius currently intends to use the net proceeds from the offering for general corporate purposes, including pre-clinical and clinical development of our product candidates and working capital and capital expenditures.

The securities described above were offered pursuant to a "shelf" registration statement (File No. 333-277319) filed with the Securities and Exchange Commission ("SEC") on February 23, 2024 and declared effective on March 1, 2024. The offering was made only by means of a prospectus, including a prospectus supplement, forming a part of the effective registration statement. The prospectus supplement and the accompanying prospectus relating to the securities offered was filed with the SEC and is available at the SEC's website at www.sec.gov. Electronic copies of the prospectus supplement and the accompanying prospectus relating to the securities being offered may also be obtained by contacting H.C. Wainwright & Co., LLC at 430 Park Avenue, 3rd Floor, New York, NY 10022, by telephone at (212) 856-5711 or e-mail at placements@hcwco.com.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction.

About Citius Pharmaceuticals, Inc.

Citius is a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products. The Company's diversified pipeline includes two late-stage product candidates. The Biologics License Application for LYMPHIR, a novel IL-2R immunotherapy for an initial indication in cutaneous T-cell lymphoma, is currently under review by the FDA with August 13, 2024 assigned as the PDUFA target action date. Citius previously announced plans to form Citius Oncology, a standalone publicly traded company with LYMPHIR as its primary asset. LYMPHIR received orphan drug designation by the FDA for the treatment of CTCL and PTCL. In addition, Citius completed enrollment in its Phase 2b trial of CITI-002 (Halo-Lido), a topical formulation for the relief of hemorrhoids. For more information, please visit www.citiuspharma.com.

Forward Looking Statements

This press release may contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements are made based on our expectations and beliefs concerning future events impacting Citius. You can identify these statements by the fact that they use words such as "will," "anticipate," "estimate," "expect," "plan," "should," and "may" and other words and terms of similar meaning or use of future dates. Forward-looking statements are based on management's current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price, and includes all statements related to the intended use of net proceeds from the offering. Factors that could cause actual results to differ materially from those currently anticipated are: risks relating to the results of research and development activities, including those from existing and new pipeline assets; uncertainties relating to preclinical and clinical testing; the early stage of products under development; our need for substantial additional funds; our ability to commercialize our products if approved by the FDA; our dependence on third-party suppliers; our ability to procure cGMP commercial-scale supply; the estimated markets for our product candidates and the acceptance thereof by any market; the ability of our product candidates to impact the quality of life of our target patient populations; our ability to obtain, perform under and maintain financing and strategic agreements and relationships; market and other conditions; our ability to attract, integrate, and retain key personnel; risks related to our growth strategy; patent and intellectual property matters; our ability to identify, acquire, close and integrate product candidates and companies successfully and on a timely basis; government regulation; competition; as well as other risks described in our SEC filings. These risks have been and may be further impacted by Covid-19 and could be impacted by any future public health risks. Accordingly, these forward-looking statements do not constitute guarantees of future performance, and you are cautioned not to place undue reliance on these forward-looking statements. Risks regarding our business are described in detail in our SEC filings which are available on the SEC's website at www.sec.gov, including in our Annual Report on Form 10-K for the year ended September 30, 2023, filed with the SEC on December 29, 2023, and updated by our subsequent filings with the SEC. These forward-looking statements speak only as of the date hereof, and we expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law.

Investor Contact: 
Ilanit Allen
ir@citiuspharma.com
908-967-6677 x113

Media Contact:
STiR-communications
Greg Salsburg
Greg@STiR-communications.com

Citius Pharmaceuticals, a late-stage biopharmaceutical company (PRNewsfoto/Citius Pharmaceuticals, Inc.)

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/citius-pharmaceuticals-announces-closing-of-15-million-registered-direct-offering-302131979.html

SOURCE Citius Pharmaceuticals, Inc.

FAQ

When did Citius Pharmaceuticals announce the closing of the registered direct offering?

Citius Pharmaceuticals announced the closing of the registered direct offering on April 30, 2024.

What was the purchase price per share in the offering?

The purchase price per share in the offering was $0.70.

Who acted as the exclusive placement agent for the offering?

H.C. Wainwright & Co. acted as the exclusive placement agent for the offering.

How does Citius Pharmaceuticals plan to utilize the net proceeds from the offering?

Citius Pharmaceuticals intends to use the net proceeds for general corporate purposes, pre-clinical and clinical development of product candidates, and working capital and capital expenditures.

Citius Pharmaceuticals, Inc.

NASDAQ:CTXR

CTXR Rankings

CTXR Latest News

CTXR Stock Data

110.03M
168.36M
6.81%
15.1%
8.02%
Medicinal and Botanical Manufacturing
Manufacturing
Link
United States of America
CRANFORD